# Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

> **NCT04757662** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Grade III Astrocytoma
- Grade IV Astrocytoma
- Astrocytoma, Grade IV
- Astrocytoma, Grade III

## Interventions

- **DRUG:** Tadalafil

## Key facts

- **NCT ID:** NCT04757662
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-06-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04757662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04757662, "Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04757662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*